RSS
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
ABBOTT PARK, Illinois and REDWOOD CITY, California, March 9, 2010 (ots/PRNewswire) -- Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage ... weiter zur Meldung von Abbott Laboratories
Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis
Abbott Park, Illinois, March 2, 2010 (ots/PRNewswire) - Imagine delaying a life-saving surgery or being afraid to receive or donate blood for fear of contracting HIV (http://www.who.int/hiv/en/). It seems unbelievable today, but twenty-five years ... weiter zur Meldung von Abbott Laboratories
Abbott Completes Acquisition of Solvay Pharmaceuticals
Abbott Park, Illinois, February 16, 2010 (ots/PRNewswire) - Abbott today announced that it has completed its EUR 4.5 billion (US$6.2 billion) acquisition of Belgium-based Solvay Pharmaceuticals, providing Abbott with a large and complementary ... weiter zur Meldung von Abbott Laboratories
Abbott to Suspend Marketing of Obesity Medicine Sibutramine in European Union Countries
Abbott Park, Illinois (ots/PRNewswire) - Today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) voted to recommend the suspension of marketing authorizations for all anti-obesity medicines ... weiter zur Meldung von Abbott Laboratories
Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
Abbott Park, Illinois (ots/PRNewswire) - A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the ... weiter zur Meldung von Abbott Laboratories
New Abbott Gene-Based Test for Colorectal Cancer Receives CE Mark
Des Plaines, Illinois (ots/PRNewswire) - Abbott announced today it has received CE Marking (Conformite Europeene) in the European Union for a new molecular diagnostic test, Abbott RealTime mS9 Colorectal Cancer, a non-invasive DNA assay that ... weiter zur Meldung von Abbott Laboratories
Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial
Orlando, Florida, November 16 (ots/PRNewswire) - - New ABSORB EXTEND Trial to Study Performance of Revolutionary Bioabsorbable Device in Approximately 1,000 Patients Abbott (NYSE: ABT) today announced three-year data from the first 30 ... weiter zur Meldung von Abbott Laboratories
Abbott to Acquire Solvay Pharmaceuticals Business
Abbott Park, Illinois (ots/PRNewswire) - - Diversifies Abbott's pharmaceutical products, expanding international growth platform - Supports long-term strategy to bolster presence in key global emerging markets - Adds substantial R&D ... weiter zur Meldung von Abbott Laboratories
Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
San Francisco (ots/PRNewswire) - Abbott (NYSE: ABT) today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first ... weiter zur Meldung von Abbott Laboratories
Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
San Francisco (ots/PRNewswire) - - Independent Study of 1,800 Patients Affirms Outstanding Performance of XIENCE V vs. TAXUS Liberte Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's (NYSE: ABT) ... weiter zur Meldung von Abbott Laboratories
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
San Francisco (ots/PRNewswire) - At One Year, XIENCE V Demonstrates: - Statistical Superiority on Primary Endpoint of Target Lesion Failure, with a 38 Percent Reduction Compared to TAXUS - 74 Percent Reduction in Stent Thrombosis ... weiter zur Meldung von Abbott Laboratories
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
San Francisco (ots/PRNewswire) - - Market-Leading XIENCE V Demonstrates Single-Digit Rate of Major Adverse Cardiac Events (MACE) at Three Years and a 43 Percent Reduction vs. TAXUS - No Additional Stent Thrombosis between Two and Three ... weiter zur Meldung von Abbott Laboratories
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
Barcelona, Spain (ots/PRNewswire) - - New Cobalt Chromium Stent Offers Enhanced Deliverability with a Broad Matrix of Sizes - Built Upon the Proven Track Record of Superior Clinical Outcomes of Abbott's Market-Leading XIENCE V(R) Drug ... weiter zur Meldung von Abbott Laboratories
Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
Abbott Park, Illinois (ots/PRNewswire) - - Broad Size Matrix of XIENCE PRIME to be Launched in Europe in the Third Quarter Abbott announced today that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE ... weiter zur Meldung von Abbott Laboratories
Abbott eröffnet in Singapur neue Herstellungseinrichtung für pädiatrische Nahrungsmittel
Singapur (ots/PRNewswire) - - Mit Foto - Grösste Herstellungseinrichtung des Unternehmens für Nahrungsprodukte wird in Asien jährlich bis zu eine Million Säuglinge und Kinder bedienen - Bekanntgabe einer Vereinbarung über die ... weiter zur Meldung von Abbott Laboratories
Abbott Recognized on Dow Jones Sustainability Index (DJSI) for Fourth Consecutive Year
Abbott Park, Illinois (ots/PRNewswire) - - Abbott Only U.S.-based Fortune 100 Health Care Manufacturer to Be Listed on Both North America and World Indexes Abbott (NYSE: ABT), the global health care company, announced today that it was ... weiter zur Meldung von Abbott Laboratories
Abbott Study Shows Investigational Heat-Stable Norvir(R) Tablet Provides Similar Drug Levels to Current Norvir Capsule
Mexico City (ots/PRNewswire) - - Pivotal Study of Norvir Tablet Bioavailability Will Form the Basis of Request for Priority Regulatory Review Abbott (NYSE: ABT) presented pivotal data at the XVII International AIDS Conference (AIDS 2008) ... weiter zur Meldung von Abbott Laboratories
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Mexico City (ots/PRNewswire) - - HIV-Infected Women and Non-Whites New to Antiretroviral Therapy Respond Similarly to Men and Whites Initial treatment regimens containing once-daily or twice-daily dosing of Abbott's (NYSE: ABT) protease ... weiter zur Meldung von Abbott Laboratories
Abbott Fund and the Government of Tanzania Celebrate Milestone in Strengthening Nation's Health Care System
Dar Es Salaam, Tanzania (ots/PRNewswire) - - Partnership Will Modernize All Regional Hospital Laboratories to Improve Access to Care Across the Country At a ceremony today, the Ministry of Health and Social Welfare, United Republic of ... weiter zur Meldung von Abbott Laboratories
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Abbott Park, Illinois (ots/PRNewswire) - - XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for Treatment of Coronary Artery Disease Abbott today ... weiter zur Meldung von Abbott Laboratories
New Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
Johannesburg, South Africa (ots/PRNewswire) - - More than 5 Million South Africans Living with HIV Gain Access to First and Only Co-formulated, Non-refrigerated Protease Inhibitor Abbott (NYSE: ABT) today announced that the new ... weiter zur Meldung von Abbott Laboratories
Abbott stellt Langzeitergebnisse einer Erweiterungsstudie vor, die zeigen dass die Remission bei erwachsenen, mit HUMIRA(R) (Adalimumab) behandelten Morbus-Crohn-Patienten anhält
Abbott Park, Illinois (ots/PRNewswire) - - Bei drei von vier nach einem Jahr in Remission befindlichen HUMIRA-Patienten blieb diese auch nach dem zweiten Jahr erhalten Die Ergebnisse einer offenen Erweiterungsstudie der ... weiter zur Meldung von Abbott Laboratories
Abbott Launches Next-Generation StarClose(R) SE Vascular Closure System
Abbott Park, Illinois (ots/PRNewswire) - - New Device Designed to Provide Fast, Safe and Secure Vessel Closure Following Catheterization Procedures Abbott today announced the launch of the StarClose(R) SE Vascular Closure System, a ... weiter zur Meldung von Abbott Laboratories
XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
Barcelona, Spain (ots/PRNewswire) - - Data from SPIRIT II and III Clinical Trials Also Show Improvement in Vessel Renarrowing with XIENCE V Compared to TAXUS in Patients with Small Vessels Data presented today from an independent pooled ... weiter zur Meldung von Abbott Laboratories
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Barcelona, Spain (ots/PRNewswire) - - Patients Treated with XIENCE V in SPIRIT III Trial Experience Better Long-Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients Treated with TAXUS Long-term data presented for the ... weiter zur Meldung von Abbott Laboratories
